Focus: Phoenix Biotechnology is a plant-based cancer drug developer headquartered in San Antonio, Texas, focused on oncology therapeutics.
Profile data last refreshed 9h ago · AI intelligence enriched 1mo ago
Stable — net +4 jobs in 30d
11 added, 7 removed. Backfill posture.
High-risk, speculative opportunity best suited to risk-tolerant scientists seeking early-stage equity upside in an underexplored modality, but requires substantial due diligence on actual pipeline and financial runway.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Phoenix Biotechnology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Phoenix Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles